Thermo Fisher Scientific Inc. · TMO · FY2026 Q2 · Calendar Q3 2026

TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises Again

Thermo Fisher delivered its second consecutive guidance raise of 2026, with Q2 revenue accelerating to 10% year-over-year growth ($11.99 billion) and adjusted EPS up 13% to $6.03, beating consensus estimates on both lines. The quarter featured broad-based strength across pharma/biotech, industrial, academic, and diagnostic end markets, plus the first full quarter of Clario ownership. Management raised full-year revenue guidance to $47.4-$48.1 billion and adjusted EPS to $24.93-$25.33, tightening the floor on revenue while lifting the EPS range meaningfully. A planned microbiology divestiture will fund $1 billion in share repurchases. The stock's roughly 10% abnormal move on the report signals investor recognition that organic growth is re-accelerating after a softer Q1 and that acquisitions are delivering synergies. Whether H2 can sustain this pace and how competitive dynamics in…

Reported Before market openNYSEHealthcare $207.93B market cap
100quality score

Company context

Snapshot as of publication

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors.…

Earnings scorecard

Reported versus consensus
Reported EPS $6.03 Consensus $6
EPS surprise +5.4% Reported versus consensus
Reported revenue $11.99B Consensus $11.71B
Revenue surprise +2.5% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +8.7% Event window
SPY move -1.2% Same window
Abnormal move +9.9% Stock minus SPY
Volume 2.7× Versus trailing sessions
Subsequent drift -2.2% Up to 20 sessions
TMOSPY benchmark

Follow TMO with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Revenue growth accelerated from 6% in Q1 to 10% in Q2, reaching $11.99B vs $11.01B prior quarter. Adjusted EPS growth accelerated from 6% to 13%, with Q2 EPS of $6.03 vs $5.44 in Q1. Full-year revenue guidance floor raised by $0.1B to $47.4B. Full-year EPS guidance range raised from $24.64-$25.12 to $24.93-$25.33. Clario contributed its first full quarter of revenue and earnings, accelerating integration synergies. New product launches included Orbitrap Tribrid Apex and Excedion mass spectrometers, Vanquish Amplify UHPLC, PowerFlex thermal cycler, and DynaDrive single-use bioreactors. Microbiology divestiture announced with proceeds funding a $1B share buyback. New partnership with Precision Health Research Singapore on population-scale proteomics.

Guidance delta

Full-year 2026 revenue guidance tightened to $47.4-$48.1B (from $47.3-$48.1B), raising the floor by $0.1B. Adjusted EPS guidance raised from $24.64-$25.12 to $24.93-$25.33, a $0.29 increase at the low end and $0.21 at the high end. This marks the second consecutive quarterly guidance raise.

Key takeaways

  • Q2 revenue grew 10% YoY to $11.99B, beating consensus by ~2.5% and accelerating from 6% growth in Q1
  • Adjusted EPS of $6.03 beat estimates by 5.4%, with growth accelerating to 13% from 6% prior quarter
  • Full-year 2026 guidance raised for the second consecutive quarter, reflecting management confidence
  • Clario acquisition delivered its first full quarter of revenue and synergies, complementing broad-based end-market strength
  • Microbiology divestiture announced, with proceeds funding $1B in share repurchases
  • Product innovation ramped with launches across mass spectrometry, chromatography, and bioproduction platforms

Management priorities

  • Continue integrating Clario and filtration & separation acquisitions to realize revenue synergies
  • Execute microbiology divestiture and deploy proceeds into share repurchases
  • Open flagship U.S. bioprocess design center in Massachusetts to expand bioproduction capabilities
  • Advance AI-enabled software across mass spectrometry and instrumentation platforms
  • Maintain active M&A pipeline targeting fragmented industry opportunities
  • Expand capacity for bioproduction and filtration businesses to meet growing demand

Related earnings events

Healthcare
UNH · FY2026 Q2 · Calendar Q3 2026UNH Q2 2026: EPS Beat, Guidance Raised as AI and Cost Trends ImproveJNJ · FY2026 Q2 · Calendar Q3 2026JNJ Q2 2026: $25.3B Sales, Guidance Raised to $101.1B Midpoint, New Launches Drive Growth

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-23T18:04:19.208939+00:00
  2. FN2 earnings calendar · 2026-07-28T01:23:15.070317+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T12:53:45.708816+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T12:53:45.706239+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.